Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1407-1413

  Leonhartsberger, Nicolai ^a   Ramoner, Reinhold ^a   Falkensammer, Claudia ^a   Rahm, Andrea ^a   Gander, Hubert ^a   Höltl, Lorenz ^b   Thurnher, Martin ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Kufstein Area Hospital   (Austria)

Author keywords

Active immunotherapy; Cancer vaccine; Dendritic cells; Quality of life; Renal cell carcinoma

Indexed keywords

CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG TOLERANCE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PATIENT ATTITUDE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84866560936     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1207-7     Document Type: Article

References (34)

1. Ravaud A, Wallerand H, Culine S, Bernhard JC, Fergelot P, Bensalah K, Patard JJ (2008) Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 54:315-325
2. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C (2011) Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 59:526-540
3. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084-1096
4. Asemissen AM, Brossart P (2009) Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother 58:1169-1174
5. Van Poppel H, Joniau S, Van Gool SW (2009) Vaccine therapy in patients with renal cell carcinoma. Eur Urol 55:1333-1342
6. Steinman RM (2007) Lasker basic medical research award. Dendritic cells: versatile controllers of the immune system. Nat Med 13:1155-1159 (Pubitemid 47530635)
7. Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendriticcell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790-802 (Pubitemid 47480309)
8. Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-147 (Pubitemid 36287518)
9. Berntsen A, Geertsen PF, Svane IM (2006) Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50:34-43 (Pubitemid 43850125)
10. Holtl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M (1998) CD83? blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352:1358 (Pubitemid 28510923)
11. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777-782 (Pubitemid 29422365)
12. Holtl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369-3376 (Pubitemid 35340710)
13. Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M (2005) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54:663-670 (Pubitemid 40884162)
14. Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M (2011) Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 6:e18801
15. Cha E, Fong L (2011) Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol 29:3677-3685
16. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M (1997) Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med 186:1603-1608 (Pubitemid 27479821)
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376 (Pubitemid 23073154)
18. Rieser C, Ramoner R, Holtl L, Rogatsch H, Papesh C, Stenzl A, Bartsch G, Thurnher M (1999) Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 63:151-159 (Pubitemid 30083819)
19. Leonhartsberger N, Ramoner R, Putz T, Gander H, Rahm A, Falkensammer C, Bartsch G, Thurnher M (2007) Antigen-independent immune responses after dendritic cell vaccination. Cancer Immunol Immunother 56:897-903 (Pubitemid 46723591)
20. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Healthrelated quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ = C30 (?3). J Clin Oncol 16:1188-1196 (Pubitemid 28108757)
21. Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH, Rosenberg J (2008) Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep 20:1305-1311
22. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S (2010) Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99:261-272
23. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278 (Pubitemid 28216581)
24. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696
25. Atzpodien J, Kuchler T, Wandert T, Reitz M (2003) Rapid deterioration in quality of life during interleukin-2-and alphainterferon-based home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer 89:50-54 (Pubitemid 36897934)
26. Heinzer H, Mir TS, Huland E, Huland H (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 17:3612-3620 (Pubitemid 29517934)
27. Cella D (2009) Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 35:733-737
28. Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN (2011) Healthrelated quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer [Epub ahead of print]
29. Bukowski R, Cella D, Gondek K, Escudier B (2007) Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30:220-227 (Pubitemid 46884139)
30. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Takenaka A, Inoue TA, Fujisawa M (2010) Impact of sorafenib on healthrelated quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int 106:1643-1647
31. Cella D (2011) Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Oncologist 16(Suppl 2): 23-31
32. Trinh L, Plotnikoff RC, Rhodes RE, North S, Courneya KS (2011) Associations between physical activity and quality of life in a population-based sample of kidney cancer survivors. Cancer Epidemiol Biomarkers Prev 20:859-868
33. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A (2011) Basic research in kidney cancer. Eur Urol 60:622-633
34. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111:5610-5620